Naltrexone and Propranolol Combined With Immunotherapy
Status:
Recruiting
Trial end date:
2025-09-30
Target enrollment:
Participant gender:
Summary
Various forms of stress can promote cancer development and growth and negatively impact the
immune system's response to tumors. Beta-adrenergic and opioid receptors co-exist in many
cells including immune cells and are integral components of the body's response to stress.
Pre-clinical studies have demonstrated that dual blockade of these receptors can decrease
tumor growth and modulate the anti-tumor immune response. This clinical trial investigates
the safety and potential therapeutic benefits of combining a beta-adrenergic blocker
(propranolol) and an opioid receptor antagonist (naltrexone) with immune checkpoint
inhibitors in patients with advanced melanoma.